Research programme: monoclonal antibody therapeutic - Arrowhead Pharmaceuticals/Merck
Latest Information Update: 16 Jul 2016
At a glance
- Originator Alvos Therapeutics
- Developer Arrowhead Pharmaceuticals; Merck & Co
- Class Monoclonal antibodies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 06 Apr 2016 Arrowhead Research Corporation is now called Arrowhead Pharmaceuticals
- 14 Aug 2012 Early research in Cancer in USA (Parenteral)